TORONTO, ONTARIO -- (Marketwire) -- 01/17/13 -- Biologix Hair Inc. (OTCBB: TGPO) (OTCQB: TGPO), formerly T & G Apothecary Inc., announces the appointment of Donna Lieder as the company's Vice President of Clinician Licensing.
Donna has over 20 years of international experience working in the financial services industry, beginning in retail banking in British Columbia and followed by bilingual banking in Paris.
She continued her career in Asheville, NC, where she worked with Offshore Seminars as a Conference Coordinator for domestic and international events, VP of Sales with JML Swiss Investment Counselors Inc., a US limited broker dealer registered in 47 states, and Operations Manager at UBS Financial Services Inc. in a supervisory role. Most recently she worked with The Himan Group at Merrill Lynch in Asheville, NC as a Financial Advisor and then Registered Client Associate.
Donna's expertise is in working with ultra high net worth clients, including physicians, in coordinating complex pieces of a client's total financial picture; her ability to provide concise, easily understood overviews that make complicated issues a simple process is very valuable in her management position at Biologix Hair Inc.
Ron Holland, Biologix Chairman and CEO, stated, "An important aspect of executing our long-term business plan is the effective development of a worldwide customer base. Our customers are the medical professionals - clinicians and doctors - who will be legally able to administer our patent pending Biologix Hair Therapy System within their respective markets, subject to FDA and subsequent territorial approvals.
"Donna has extensive international sales experience and possesses the qualities it takes to lead a global customer development effort. Her team will focus on contracting with clinicians and doctors who seek to secure certain exclusive purchasing and treatment certification rights for the Biologix Hair Therapy System in advance of regulatory approvals," continued Holland.
Commenting on her appointment, Mrs. Lieder said: "I am pleased to have been promoted to lead the worldwide clinician licensing department for Biologix Hair and am confident we will be successful in developing a global distribution network that is in a ready position to start treating patients, if and when FDA and other market approvals are forthcoming. I look forward to bringing periodic progress updates to our shareholders as we move forward."
About Biologix Hair Inc. and Biologix Hair Science Ltd.
Biologix Hair Inc. (Biologix Hair), together with its wholly owned biotechnology subsidiary, Biologix Hair Science Ltd. (BHS), is focused on realizing the full market potential for its patent-pending hair loss formula - Biologix Revive - and its demonstrated ability to prevent and reverse the effects of alopecia, which plagues hundreds of millions worldwide.
Between mid-2004 and mid-2012, more than 30,000 pre-clinical-trial treatments of Biologix Revive were administered to 5,000-plus patients in South America suffering with varying degrees of alopecia, as well as people seeking preventive treatment. The participating treatment clinicians subjectively observed and reported that virtually 100% of preventive care clients continued to retain their healthy hair and an estimated 80-85% of the males and 90-plus% of the females treated for hair regeneration experienced significant regrowth of their own natural hair. And among alopecia areata patients, virtually total hair regrowth was observed in 100% of the cases. To date, no negative side effects have been reported.
Most Popular Stories
- Twitter Names Woman to Board
- Aspen Contracting Adding 300 Jobs
- Obamacare Doing Just Fine, Ky. Governor Says
- Rand Paul Signs up for Obamacare
- Hispanic Employment Improves in November
- U.S. Chamber to Run Ads in Idaho, W.Va.
- U.S. Unemployment Rate Dips to 7 Percent
- Consumer Spending Rises, Incomes Fall
- American Eagle Issues Weak Q4 Outlook
- NSA Tracks 5 Billion Cellphone Records a Day